Conjugate containing detectable portion

A conjugate with a quinone methide analogue precursor amplifies signals at the target site in biological samples, addressing background noise issues in immunohistochemistry and in situ hybridization, enhancing detection and quantification of low-abundance markers.

JP7848186B2Active Publication Date: 2026-04-20VENTANA MEDICAL SYSTEMS INC
8 Cites 0 Cited by

Patent Information

Application Number
JP2023513314
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-08-28
Filing Date
2021-08-27
Publication Date
2026-04-20
Estimated Expiration
2041-08-27

AI Technical Summary

Technical Problem

Existing methods for signal amplification in immunohistochemistry and in situ hybridization often result in increased background signals, obscuring faint but clinically important signals, hindering accurate detection and quantification of low-abundance cellular markers.

Method used

The use of a conjugate containing a quinone methide analogue precursor and a detectable label, which forms a reactive quinone methide analogue proximal to the target in the biological sample, allowing for signal amplification without significant background noise.

Benefits of technology

Enhances signal detection and quantification of low-abundance targets by amplifying signals specifically at the target site, reducing background noise and improving diagnostic accuracy.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Disclosed herein are detectable moieties and detectable conjugates comprising one or more detectable moieties. In some embodiments, the disclosed detectable moieties have narrow wavelengths and are suitable for multiplexing. Also disclosed are methods for labeling one or more targets in a biological specimen using any of the detectable conjugates and / or detectable moieties described herein.
Need to check novelty before this filing date? Find Prior Art